Setipiprant (ACT-129968)
|
S413325-100mg
|
Moligand™, ≥98% |
866460-33-5 |
100mg
|
¥ 2088.9
|
现货 |
阿拉丁 |
3-脱氮腺苷盐酸盐
|
D412544-50mg
|
≥99% |
86583-19-9 |
50mg
|
¥ 16479.9
|
现货 |
阿拉丁 |
3-脱氮腺苷盐酸盐
|
D412544-1mg
|
≥99% |
86583-19-9 |
1mg
|
¥ 1441.9
|
现货 |
阿拉丁 |
3-脱氮腺苷盐酸盐
|
D412544-10mg
|
≥99% |
86583-19-9 |
10mg
|
¥ 4633.9
|
现货 |
阿拉丁 |
FR 180204,ERK抑制剂
|
F286586-5mg
|
Moligand™, ≥98%(HPLC) |
865362-74-9 |
5mg
|
¥ 421.9
|
现货 |
阿拉丁 |
FR 180204,ERK抑制剂
|
F286586-25mg
|
Moligand™, ≥98%(HPLC) |
865362-74-9 |
25mg
|
¥ 1296.9
|
现货 |
阿拉丁 |
KKL-35
|
K413519-25mg
|
≥98% |
865285-29-6 |
25mg
|
¥ 1853.9
|
现货 |
阿拉丁 |
KKL-35
|
K413519-1mg
|
≥98% |
865285-29-6 |
1mg
|
¥ 159.9
|
现货 |
阿拉丁 |
KKL-35
|
K413519-100mg
|
≥98% |
865285-29-6 |
100mg
|
¥ 5560.9
|
现货 |
阿拉丁 |
BMS-663068,是 BMS626529 的膦酰氧甲基前药
|
B127031-50mg
|
Moligand™, ≥98% |
864953-29-7 |
50mg
|
¥ 9269.9
|
现货 |
阿拉丁 |
BMS-663068,是 BMS626529 的膦酰氧甲基前药
|
B127031-25mg
|
Moligand™, ≥98% |
864953-29-7 |
25mg
|
¥ 5560.9
|
现货 |
阿拉丁 |
BMS-663068,是 BMS626529 的膦酰氧甲基前药
|
B127031-10mg
|
Moligand™, ≥98% |
864953-29-7 |
10mg
|
¥ 2488.9
|
现货 |
阿拉丁 |
Auxinole
|
A413687-50mg
|
≥98% |
86445-22-9 |
50mg
|
¥ 2316.9
|
现货 |
阿拉丁 |
Auxinole
|
A413687-250mg
|
≥98% |
86445-22-9 |
250mg
|
¥ 5213.9
|
现货 |
阿拉丁 |
Auxinole
|
A413687-10mg
|
≥98% |
86445-22-9 |
10mg
|
¥ 731.9
|
现货 |
阿拉丁 |
Auxinole
|
A413687-100mg
|
≥98% |
86445-22-9 |
100mg
|
¥ 3475.9
|
现货 |
阿拉丁 |
2,4-二氟-α-(1H-1,2,4-三唑基)乙酰苯
|
D123256-500g
|
≥98%(GC) |
86404-63-9 |
500g
|
¥ 696.9
|
现货 |
阿拉丁 |
3-O-乙基-L-抗坏血酸
|
O159940-500g
|
≥98%(HPLC)(T) |
86404-04-8 |
500g
|
¥ 2059.9
|
现货 |
阿拉丁 |
[2,6-二氯-4-(三氟甲基)苯基]肼
|
D337968-5g
|
≥98% |
86398-94-9 |
5g
|
¥ 1544.9
|
现货 |
阿拉丁 |
WAY-339503
|
W418374-5mg
|
≥98% |
863589-52-0 |
5mg
|
¥ 925.9
|
现货 |
阿拉丁 |
WAY-339503
|
W418374-50mg
|
≥98% |
863589-52-0 |
50mg
|
¥ 5235.9
|
现货 |
阿拉丁 |
WAY-339503
|
W418374-25mg
|
≥98% |
863589-52-0 |
25mg
|
¥ 3080.9
|
现货 |
阿拉丁 |
WAY-339503
|
W418374-10mg
|
≥98% |
863589-52-0 |
10mg
|
¥ 1667.9
|
现货 |
阿拉丁 |
WAY-339503
|
W418374-100mg
|
≥98% |
863589-52-0 |
100mg
|
¥ 8899.9
|
现货 |
阿拉丁 |